Home
About
FAQ
History (5)
Biotinidase Deficiency
Cost effectiveness of biologic therapies for plaque psoriasis.
Safe Step Act: does it undermine step therapy?
Skin manifestations of outpatient adverse drug events in the United States: a national analysis.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.
See All 5 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013 Aug; 14(4):315-26.
View in:
PubMed
subject areas
Adult
Antibodies, Monoclonal
Biological Therapy
Cost of Illness
Cost-Benefit Analysis
Female
Health Care Costs
Humans
Immunoglobulin G
Male
Middle Aged
Psoriasis
Quality of Life
Receptors, Tumor Necrosis Factor
Recombinant Fusion Proteins
Treatment Outcome
United States
authors with profiles
Steven R. Feldman MD, PhD
Christine Ahn MD